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To the Editor,
The outbreak of the COVID-19 pandemic shows a marked 
geographical variation in its prevalence and mortality. 
As no viral mutations have been reported, which can 
explain the important geographical variations, the ques-
tion arises if genetic variation of the host may affect the 
outcome of COVID-19 infection. We therefore postulated 
that the variability in genotype distribution of a number 
of immune-related human plasma proteins showing a 
marked geographical variation [1–3] might partly explain 
the variable prevalence of the COVID-19 infection.
Prevalence and mortality data (per 1,000,000 inhab-
itants) of the COVID-19 infection from a number of Euro-
pean, North-African and Middle East countries were 
included in the study: Algeria, Austria, Belgium, Bulgaria, 
Cyprus, Croatia, Czech Republic, Denmark, Egypt, Estonia, 
Finland, France, Germany, Greece, Hungary, Iran, Israel, 
Italy, Jordan, Moldova, the Netherlands, Poland, Portu-
gal, Romania, Slovakia, Slovenia, Spain, Saudi Arabia, 
Sweden, Switzerland, Tunisia, Turkey and the United 
Kingdom were included in the analysis. Data reported on 
March 28, 2020 by Johns Hopkins were analyzed [4]. Fur-
thermore, the time interval since the start of the infection 
in each country was recorded for synchronizing the data.
Concomitantly, data on the geographical variation 
of a number of immune system-related human plasma 
protein polymorphisms on the deletion/insertion (D/I) 
polymorphism of the angiotensin-converting enzyme 1 
(ACE1) gene [3], human homeostatic iron regulator protein 
(HFE) [2], complement factor C3 [5], haptoglobin [6] and 
vitamin D binding protein [7] were collected from the 
literature.
In the multiple regression analysis model, the prev-
alence of COVID-19  significantly correlated with ACE1 
polymorphism. The other investigated polymorphisms 
(complement C3 [F and S alleles], HFE [C282Y muta-
tion], haptoglobin [Hp1 and Hp2 alleles] and vitamin D 
binding protein [DBP1 and DBP 2 alleles]) did not show 
a significant correlation with COVID-19 prevalence. Figure 
1 shows the regression equation. The log-transformed 
prevalence of COVID-19 in 33 countries (on April 1, 2020) 
negatively correlated with the ACE D allele frequency: log 
(prevalence; no. of cases/106 inhabitants) = 6.074 − 0.064 
(D-allele frequency, %), r2 = 0.410; p = 0.0001. The model 
improved when the onset of the epidemic in each country 
was taken into account: log (prevalence; number of 
cases/106 inhabitants) = 6.163 − 0.055 (D-allele frequency, 
%) − 0.012 (days since Jan 1, 2020), r2 = 0.476; p < 0.0001. 
Similarly, COVID-19-associated mortality did only corre-
late with ACE1: log (mortality; number of cases/106 inhab-
itants) = 4.767 − 0.070 (D-allele frequency, %), r2 = 0.285; 
p = 0.01, and not with any of the other investigated plasma 
protein polymorphisms. Also, this correlation improved 
when the onset of the epidemic was taken into account: 
4.955 − 0.055 (D-allele frequency, %) − 0.026 (days since 
Jan 1, 2020), r2 = 0.457; p < 0.0001.
Our findings suggest that the ACE1 D/I polymorphism 
may be regarded as a confounder in the spread of COVID-
19 and the outcome of the infection [8]. The findings are 
remarkable as all plasma protein polymorphisms investi-
gated show a certain East-West gradient in Europe [6, 7], 
which is pleading against the bystander role of the ACE D/I 
polymorphism as a biomarker for historical migrations in 
the remote past, which passively comigrates with causal 
genetic factors involved in COVID-19 infection. These find-
ings are in agreement with the role of ACE in lung infec-
tions caused by coronaviruses [9]. The strength of the 
association is further highlighted by the variable policy 
vs. the COVID-19 threat in the various countries during 
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the early phase of the COVID-19 outbreak and the variable 
onset of the infection in the studied countries. The D/I pol-
ymorphism in intron 16 of ACE1 is associated with altera-
tions in circulating and tissue concentrations of ACE. The 
deletion is associated with a reduced expression of ACE2. 
Coronaviruses (severe acute respiratory syndrome corona-
virus [SARS-CoV] and SARS-CoV-2) are able to bind to their 
target cells through ACE2 [9, 10]. ACE2 facilitates rapid 
viral replication, whereas depletion of ACE2 from the cell 
membrane enhances the damaging effects of Ang II in the 
lung [8]. As the ACE D/I genotype might be involved in the 
pathogenesis of COVID-19 infection, further studies are 
required to assess the clinical outcome of COVID-19 infec-
tion in ACE DD, DI and II carriers and to study the exact 
role of the ACE polymorphism in COVID-19 infection and 
its therapy response. Including ACE D/I polymorphism 
into mathematical models describing COVID epidemics 
could improve model accuracy.
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Figure 1: Prevalence of COVID-19 in 33 countries (on April 1, 2020) 
vs. ACE1 D-allele frequency (%): log (prevalence; no. of cases/106 
inhabitants) = 6.074 − 0.064 (D-allele frequency, %), r2 = 0.410; 
p = 0.0001.
